Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 4.1.2.27 extracted from

  • Sunter, G.; Enver, E.O.; Akbarzade, A.; Turan, S.; Vatansever, P.; Gunal, D.I.; Haklar, G.; Bereket, A.; Agan, K.; Guran, T.
    Acquired modification of sphingosine-1-phosphate lyase activity is not related to adrenal insufficiency (2018), BMC Neurol., 18, 48.
    View publication on PubMed
Search for more literature for 4.1.2.27

Organism

Organism UniProt Comment Textmining
Homo sapiens O95470
-
-

Synonyms

Synonyms Comment Organism
S1P lyase
-
 Homo sapiens
sphingosine-1-phosphate lyase
-
 Homo sapiens

General Information

General Information Comment Organism
drug target sphingosine-1-phosphate lyase is therapeutically inhibited by fingolimod which is an oral drug for relapsing multiple sclerosis (MS). Modification and inhibition of sphingosine-1-phosphate lyase activity by the long-term therapeutic use of fingolimod is safe for the adrenal function in adult patients with MS Homo sapiens
malfunction congenital sphingosine-1-phosphate lyase deficiency due to biallelic mutations in SGPL1 gene is described in association with primary adrenal insufficiency and steroid-resistant nephrotic syndrome Homo sapiens